RhumbLine Advisers
ELVN icon

RhumbLine Advisers’s Enliven Therapeutics ELVN Stock Holding History

RhumbLine Advisers’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.9M Buy
57,241
+7,053
+14% +$299K ﹤0.01% 1750
2026
Q1 		$1.97M Sell
50,188
-321
-0.6% -$8.89K ﹤0.01% 1868
2025
Q4 		$778K Sell
50,509
-9,651
-16% -$192K ﹤0.01% 2370
2025
Q3 		$1.23M Buy
60,160
+9,880
+20% +$199K ﹤0.01% 2135
2025
Q2 		$1.01M Sell
50,280
-2,222
-4% -$42.1K ﹤0.01% 2244
2025
Q1 		$1.03M Buy
52,502
+2,466
+5% +$53.1K ﹤0.01% 2156
2024
Q4 		$1.13M Buy
50,036
+170
+0.3% +$4.41K ﹤0.01% 2192
2024
Q3 		$1.27M Buy
49,866
+239
+0.5% +$5.54K ﹤0.01% 2137
2024
Q2 		$1.16M Buy
49,627
+11,420
+30% +$240K ﹤0.01% 2162
2024
Q1 		$672K Buy
38,207
+864
+2% +$13.3K ﹤0.01% 2481
2023
Q4 		$517K Buy
37,343
+2,980
+9% +$36.5K ﹤0.01% 2641
2023
Q3 		$469K Sell
34,363
-433
-1% -$7.29K ﹤0.01% 2648
2023
Q2 		$710K Buy
+34,796
New +$703K ﹤0.01% 2477

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RhumbLine Advisers's ELVN Position: Q2 2026 in Review

RhumbLine Advisers increased its Enliven Therapeutics (ELVN) stake by 14% in Q2 2026, buying an estimated $299K and bringing the position to 57,241 shares worth $2.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1750.

RhumbLine Advisers first reported a position in ELVN in Q2 2023 and has held it in 13 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • RhumbLine Advisers held 57,241 shares of Enliven Therapeutics worth $2.9M as of Q2 2026.
  • RhumbLine Advisers bought 7,053 Enliven Therapeutics shares in Q2 2026, an estimated $299K.
  • Enliven Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1750 holding.
  • RhumbLine Advisers first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.